Ranimustine (INN, marketed under the tradename Cymerin; also known as MCNU) is a nitrosourea alkylating agent approved in Japan for the treatment of chronic myelogenous leukemia and polycythemia vera.
{{Drugbox | verifiedrevid = 448120715 | IUPAC_name = Methyl 6-({[(2-chloroethyl)(nitroso)amino]carbonyl}amino)-6-deoxy-α-D-glucopyranoside | image = Ranimustine (Haworth).svg | image_class = skin-invert-image | width = 215
| tradename = Cymerin | Drugs.com = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = Rx-only | routes_of_administration = IV
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).